Johnson & Johnson (JNJ)
239.84
+1.35
(+0.57%)
USD |
NYSE |
Jun 11, 11:35
Johnson & Johnson SG&A Expense (Quarterly) : 6.034B for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 6.034B |
| December 31, 2025 | 6.753B |
| September 30, 2025 | 5.922B |
| June 30, 2025 | 5.889B |
| March 31, 2025 | 5.112B |
| December 31, 2024 | 6.453B |
| September 30, 2024 | 5.478B |
| June 30, 2024 | 5.681B |
| March 31, 2024 | 5.257B |
| December 31, 2023 | 5.81B |
| September 30, 2023 | 5.40B |
| June 30, 2023 | 5.396B |
| March 31, 2023 | 4.906B |
| December 31, 2022 | 5.339B |
| September 30, 2022 | 4.975B |
| June 30, 2022 | 6.226B |
| March 31, 2022 | 5.938B |
| December 31, 2021 | 7.154B |
| September 30, 2021 | 6.00B |
| June 30, 2021 | 6.073B |
| March 31, 2021 | 5.432B |
| December 31, 2020 | 6.457B |
| September 30, 2020 | 5.431B |
| June 30, 2020 | 4.993B |
| March 31, 2020 | 5.203B |
| Date | Value |
|---|---|
| December 31, 2019 | 6.039B |
| September 30, 2019 | 5.374B |
| June 30, 2019 | 5.546B |
| March 31, 2019 | 5.219B |
| December 31, 2018 | 5.991B |
| September 30, 2018 | 5.543B |
| June 30, 2018 | 5.743B |
| March 31, 2018 | 5.263B |
| December 31, 2017 | 6.045B |
| September 30, 2017 | 5.423B |
| June 30, 2017 | 5.289B |
| March 31, 2017 | 4.737B |
| December 31, 2016 | 5.309B |
| September 30, 2016 | 4.772B |
| June 30, 2016 | 5.176B |
| March 31, 2016 | 4.688B |
| December 31, 2015 | 5.891B |
| September 30, 2015 | 5.081B |
| June 30, 2015 | 5.384B |
| March 31, 2015 | 4.847B |
| December 31, 2014 | 5.822B |
| September 30, 2014 | 5.468B |
| June 30, 2014 | 5.481B |
| March 31, 2014 | 5.183B |
| December 31, 2013 | 5.917B |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 2.934B |
| Merck & Co., Inc. | 2.70B |
| Pfizer Inc. | 2.961B |
| Bristol Myers Squibb Co. | 1.617B |
| Royalty Pharma Plc | 159.49M |